Ying-Juan-Jie Zhu

Early disease control with a biochemical response to aumolertinib after postoperative recurrence of EGFR-Mutant stage IIIA lung adenocarcinoma after icotinib, with EGFR T790M detected at recurrence: a Case Report

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are a standard treatment for EGFR-mutant non-small cell lung cancer (NSCLC). However, acquired resistance commonly develops after treatment with first- or second-generation EGFR-TKIs. Aumolertinib, a third-generation EGFR-TKI, has demonstrated...